NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, July, 30th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.02. The medical research company earned $101.71 million during the quarter, compared to analyst estimates of $97.32 million. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. NeoGenomics's revenue was up 50.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 EPS. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NeoGenomics issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.

7 brokers have issued 1-year target prices for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' stock price to reach $24.57 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News headlines about NEO stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in September. As of September 30th, there was short interest totalling 5,500,000 shares, an increase of 13.2% from the August 30th total of 4,860,000 shares. Based on an average daily volume of 863,900 shares, the short-interest ratio is presently 6.4 days. Approximately 5.6% of the shares of the stock are sold short. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Teva Pharmaceutical Industries (TEVA), Eurofins Scientific (ERFSF), ABIOMED (ABMD), Ionis Pharmaceuticals (IONS), Avantor (AVTR), Bausch Health Companies (BHC), Masimo (MASI), Icon (ICLR), Novocure (NVCR), BIO-TECHNE (TECH), Molina Healthcare (MOH), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT) and Recordati (RCDTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Netflix (NFLX), Amarin (AMRN), Exelixis (EXEL), Intel (INTC) and AT&T (T).

NeoGenomics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), State of Alaska Department of Revenue (0.08%), Robeco Institutional Asset Management B.V. (0.08%), CIBC Private Wealth Group LLC (0.07%), Envestnet Asset Management Inc. (0.04%) and Stephens Inc. AR (0.03%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Stephens Inc. AR and CIBC Private Wealth Group LLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, HMS Capital Management LLC, Summit Creek Advisors LLC, Juncture Wealth Strategies LLC, Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C., Nisa Investment Advisors LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $20.25.

NeoGenomics has a market capitalization of $2.10 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]